Navigation Links
AMDL Announces Preliminary Third Quarter Earnings; Revises 2008 Guidance
Date:11/12/2008

d important part of our marketing strategy to increase sales revenue; bolster AMDL's competitive position in China and new markets and to drive long-term growth for the Company & our shareholders."

AMDL will discuss its business outlook during its regular quarterly conference call which is scheduled for the end of November. Specific details will be announced later this month.

Mr. MacLellan continued, "With the recent adjustments made in our business -- including an expanded and strengthened senior management team and board of directors, revised business strategy, and prioritized focus on securing additional capital to support AMDL's future growth -- we have embarked on the most exciting era in the Company's history. What lies ahead is the perfect opportunity to establish AMDL as a market-winning leader that delivers lucrative, long-term returns for our employees, partners, customers and shareholders."

Mr. MacLellan will cover today's news in a scheduled presentation he will deliver at Rodman & Renshaw's Annual Global Investment Conference taking place today, November 12th, 2008 at the New York Palace Hotel in New York City. Additionally, interested parties can download a copy of Mr. MacLellan's presentation through the AMDL corporate website located http://www.amdl.com under the "news" section. For additional information please contact Kristine Szarkowitz, SVP, AMDL Investor Relations at 206-310-5323 or kszarkowitz@amdl.com.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated bio-pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs over 490 people in the U.S. and China. '/>"/>

SOURCE AMDL, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982
2. Standard & Poors Announces Changes to U.S. Indices
3. Quanterix Corporation Announces the Addition of Dr. Robert Corn to its Scientific Advisory Board
4. Cardiums InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries
5. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
6. China Biologic Products Announces Third Quarter 2008 Results Conference Call
7. Synvista Therapeutics Announces Data Further Demonstrating the Value of Haptoglobin Genotyping in Diabetic Patients During AHA Meeting
8. Heritage Labs Announces A1c Test Certification Milestone
9. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
10. The Binding Site Announces Trading Update for Year Ended September 30th 2008
11. CorMatrix Announces Pre-Clinical Data Suggesting Next Generation ECM Technology(TM) Can Improve Cardiac Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  TransCelerate BioPharma ... a recommended approach for protecting personal data in ... researchers, patients and others. The document describes an ... information from CSRs and other related clinical trial ... The goal of the TransCelerate CSR Redaction ...
(Date:9/2/2014)... September 02, 2014 Myriant Corporation, ... signage of a distribution agreement with Azelis Group, ... distributing Myriant’s bio-succinic acid in the Nordics, Benelux, ... targeting customers in the industrial and base chemicals ... Azelis offers a far-reaching chemical portfolio with extensive ...
(Date:9/2/2014)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) ... (PTO) has issued a patent related to NB32, the ... is a fixed-dose combination of naltrexone sustained release (SR) ... claims methods for treating insulin resistance using a composition ... If NB32 is approved for use in ...
(Date:9/2/2014)... Inc. (Nasdaq: ONTY ) announced today that ... present at the Rodman & Renshaw 16 th Annual ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... will be accessible by visiting the Oncothyreon website www.oncothyreon.com ... About Oncothyreon Oncothyreon is a biotechnology company ...
Breaking Biology Technology:TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... presented today show that RAPAFLO(R) (silodosin) significantly reduced ... pain syndrome (CP/CPPS).  In the study presented at ... RAPAFLO(R) also significantly improved urinary symptoms as well ... pelvic pain syndrome (CP/CPPS) is a common condition ...
... 2011 Brian Olson didn,t exactly fit the image of an ... first to admit it. "I had just a GED and was ... math." With a vague notion that he wanted to ... enrolled in basic chemistry and biology courses as a freshman. ...
... May 17, 2011 P f enex ... has submitted a Biologics Master File (BMF) to the United ... carrier protein to support the development of conjugate vaccine products ... supplying cGMP grade CRM197 carrier protein to multiple partners in ...
Cached Biology Technology:Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 2Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 3Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 4Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 5Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome 6From GED to PhD: Borough of Manhattan Community College's Brian Olson Faces Academic Deficits Only to Be Rewarded with Acceptance to CUNY's PhD Program in Biochemistry 2Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 2Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA 3
(Date:9/2/2014)... lithographic limestone is well known as a result ... area (for example, Archaeopteryx). Now, for the first ... French equivalent of these outcrops - discoveries which ... water treader. , Despite the abundance of fossils ... been obtained from the Late Kimmeridgian equivalents of ...
(Date:9/2/2014)... stride; others are done in by it. New research ... this so-called stress gap in mice with very similar ... to better understand the development of psychiatric disorders such ... has unique experiences as it goes through its life. ... the expression of genes, and as a result, affect ...
(Date:9/1/2014)... U.S. has improved steadily in recent yearsspurred in large ... remains poor and disparities continue to widen among socioeconomic ... Harvard School of Public Health (HSPH). , "The study ... extensive efforts by many groups and individuals to improve ... also indicates that these efforts need to be expanded," ...
Breaking Biology News(10 mins):Exceptionally well preserved insect fossils from the Rhône Valley 2Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3
... has identified a lung protein that appears to play ... an antibody to block its activity, Indiana University scientists ... the protein, a cytokine named EMAPII, could provide a ... M.D., associate professor of medicine at the Indiana University ...
... take to regenerate a limb? Biologists have long thought that ... cells that can generate any tissue in the body. But ... regrow the complete organ, at least in zebrafish. Researchers ... shown that cells capable of regenerating a zebrafish fin do ...
... has worked with wireless sensor network developers Senceive, ... across critical structures in the UK that will ... Senceive,s main application area is long-term infrastructure monitoring. ... used to assess the condition of railway structures, ...
Cached Biology News:Protein could offer target to reduce lung damage from smoking-caused emphysema 2Zebrafish regrow fins using multiple cell types, not identical stem cells 2NPL helps Senceive to offer improved monitoring of structural assets across the UK 2
... Monoclonal Mouse Antibody to Cytokeratin 5 / ... a high molecular weight, basic type of ... the superficial cell layers of stratified epithelia ... and in mesothelial cells and mesothelioma. Cytokeratin ...
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
Bovine Aortic Smooth Muscle Cells (BAOSMC) (>500,000 cells)...
Biology Products: